Search
Treosulfan
go.drugbank.com/drugs/DB11678ApprovedInvestigational[L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575]
Crotamiton
go.drugbank.com/drugs/DB00265ApprovedCrotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol.
Categories: Compounds used in a research, industrial, or household settingMethylparaben
go.drugbank.com/drugs/DB14212ApprovedMethylparaben is used in allergenic testing.
Categories: Compounds used in a research, industrial, or household settingDroxicam
go.drugbank.com/drugs/DB09215ApprovedWithdrawnDroxicam is an oxicam non-steroidal anti-inflammatory drug and a prodrug of [DB00554]. … It is used to reduce pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.
Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[L51134] PTH(1-34) contains the N-terminal part of the endogenous PTH molecule. … [L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.
Synonyms: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34, Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isoleParamethadione
go.drugbank.com/drugs/DB00617ApprovedParamethadione is an anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.
Resmetirom
go.drugbank.com/drugs/DB12914ApprovedInvestigational[L50336] Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, such as low serum thyroid hormone levels, is often observed in NAFLD. … On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD
Belumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigational[L34754] In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.[L42925] … [L34749] In the treatment of GVHD, a condition in which donor T-cells begin to attack recipient tissues following allogeneic hematopoeitic stem cell transplantation (HSCT), belumosudil helps to resolve
Imiquimod
go.drugbank.com/drugs/DB00724ApprovedInvestigationalImiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas.
Gallium nitrate
go.drugbank.com/drugs/DB05260ApprovedInvestigational[A260816] Gallium nitrate is reported to possess antiresorptive and hypocalcemic effects on bone. … [L47726] Apart from cancer-related hypercalcemia, gallium nitrate has been studied in arthritis, autoimmune disorders, and tumours.[A260830]